• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Association Between Low Hemoglobin Levels in Early Pregnancy and Severe Maternal Morbidity

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Many studies use hemoglobin levels later in pregnancy when assessing the relationship between anemia and adverse perinatal outcomes
  • Ray et al. (BJOG, 2020) evaluated the association between early maternal hemoglobin concentration and severe maternal morbidity or maternal mortality

METHODS:

  • Population-based cohort study
  • Population
    • Pregnant women
    • Routine outpatient hemoglobin measured between 2 and 16 weeks
  • Study design
    • The relationship between early-pregnancy outpatient blood hemoglobin concentration and each study outcome was expressed as adjusted relative risks (aRR) and absolute risk differences (aRD)
    • Mode of birth, BMI and iron supplementation were added to the model
    • Normal hemoglobin reference range: 125 to 129 g/L
  • Primary outcome
    • Severe maternal morbidity composite or maternal mortality, from 23 weeks gestation to 42 days postpartum
    • Severe morbidity composite comprises approximately 40 morbidity measures (ante-, intra- and postpartum)

RESULTS:

  • 737,393 births
    • Mean (SD) hemoglobin concentration: 126.9 (9.3) g/L
  • Overall severe maternal morbidity or deaths: 1.8%

Pregnancies with lower hemoglobin levels were at higher risk of the primary outcome vs normal reference range

Risk increased with lower hemoglobin levels

  • 120 to 124 g/L
    • aRR 1.07 (95% CI, 1.02 to 1.13)
    • aRD 0.09% (95% CI, 0.01 to 0.18)
  • 105 to 109 g/L
    • aRR 1.31 (95% CI, 1.17 to 1.46)
    • aRD 0.47% (95% CI, 0.24 to 0.69)
  • <90 g/L
    • aRR 4.53 (95% CI, 3.59 to 5.72)
    • aRD 5.94% (95% CI, 4.12 to 7.76)

Transfusion Risk

  • 0.8% of women required red cell transfusion
  • Risk of requiring red cell transfusion was significantly higher at all hemoglobin concentrations <125 to 129 g/L
    • Peak adverse perinatal outcomes occurred at a hemoglobin level <90 g/L
    • aRR 11.82 (95% CI, 9.30 to 15.03)

CONCLUSION:

  • In pregnant women, risk of severe maternal morbidity, death, and red cell transfusion increases with decreasing hemoglobin levels with a peak at hemoglobin level <90 g/L
  • The authors state

…the current findings provide precise haemoglobin thresholds to guide clinicians in their assessment of a woman’s future risk of unfavourable outcomes, including who may benefit from preventative interventions

An RCT comparing low dose versus high dose iron therapy initiated in early pregnancy might be warranted at different haemoglobin thresholds, with the highest potential population level impact likely among women whose haemoglobin concentration is <110 g/l

Learn More – Primary Sources:

Haemoglobin levels in early pregnancy and severe maternal morbidity: population‐based cohort study

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Your Anemia Screening Test Fits in Your Pocket
Maternal Anemia and Adverse Perinatal Outcomes
Practical obstetrics info for your women's healthcare practice
Screening for Hemoglobinopathies in Pregnancy – The ACOG Approach

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site